[HTML][HTML] Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for …
J Xu, Y Cai, Z Hong, H Duan, S Ke - International Journal of …, 2024 - journals.lww.com
Background: The application of neoadjuvant immune checkpoint inhibitors combined with
chemotherapy (NICT) in treating locally advanced oesophageal squamous cell carcinoma …
chemotherapy (NICT) in treating locally advanced oesophageal squamous cell carcinoma …
[HTML][HTML] Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review
EN Oliva, T Ionova, E Laane, M Csenar… - Frontiers in …, 2024 - frontiersin.org
Background Lymphoma treatment can lead to long-term consequences such as fatigue,
infertility and organ damage. In clinical trials, survival outcomes, clinical response and …
infertility and organ damage. In clinical trials, survival outcomes, clinical response and …
Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia
F Efficace, F Cottone, B Yanez, V Kota, F Castagnetti… - Cancer, 2024 - Wiley Online Library
Background The authors assessed the clinical utility of patient‐reported symptom monitoring
in the setting of newly diagnosed chronic myeloid leukemia (CML). The primary objective …
in the setting of newly diagnosed chronic myeloid leukemia (CML). The primary objective …
Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study
Y Yang, J Liu, Z Liu, L Zhu, H Chen, B Yu… - The Journal of Thoracic …, 2024 - Elsevier
Objective This study aims to report the 2-year outcomes of patients with clinical stage N2-3
esophageal squamous cell carcinoma who received neoadjuvant chemotherapy and …
esophageal squamous cell carcinoma who received neoadjuvant chemotherapy and …
[HTML][HTML] A study demonstrating users' preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE® in patients with lung cancer
T Jordan, T Nuamek, I Fornacon-Wood… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Materials and Methods Patients with lung cancer were recruited to the study while attending
outpatient clinics at a tertiary cancer centre. Clinician-reported outcomes were generated …
outpatient clinics at a tertiary cancer centre. Clinician-reported outcomes were generated …
Device-assisted intravesical chemotherapy versus bacillus Calmette–Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer …
C You, Q Li, L Qing, R Li, Y Wang, L Cheng… - International Urology and …, 2024 - Springer
Purpose To investigate the effectiveness and safety of device-assisted intravesical
chemotherapy compared to Bacillus Calmette–Guerin (BCG) in the treatment of patients with …
chemotherapy compared to Bacillus Calmette–Guerin (BCG) in the treatment of patients with …
Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150mg/ml) versus placebo in mild to moderate anxiety subjects …
PR Gundugurti, N Banda, SSR Yadlapalli… - Asian Journal of …, 2024 - Elsevier
Background Anxiety disorders, an increasingly prevalent global mental health illness,
affected approximately 301 million individuals worldwide in 2019. There is an unmet need …
affected approximately 301 million individuals worldwide in 2019. There is an unmet need …
Integrating Patient-Reported Outcomes Into the Care of People With Advanced Cancer—A Practical Guide
J Lai-Kwon, E Thorner, C Rutherford… - American Society of …, 2024 - ascopubs.org
Patient-reported outcomes (PROs) are being increasingly integrated into routine clinical
practice to enhance individual patient care. This has been driven by recognition of the …
practice to enhance individual patient care. This has been driven by recognition of the …
Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial
HS Rugo, P Schmid, SM Tolaney, F Dalenc… - The …, 2024 - academic.oup.com
Abstract Background The TROPiCS-02 study (NCT03901339) demonstrated that
sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician's …
sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician's …
Association of self-directed walking with toxicity moderation during chemotherapy for the treatment of early breast cancer
KA Nyrop, A Page, AM Deal, C Wagoner… - Supportive Care in …, 2024 - Springer
Background In the field of exercise oncology, there is a need to quantify the potential
benefits of moderate, self-directed physical activity during active treatment. In a pooled …
benefits of moderate, self-directed physical activity during active treatment. In a pooled …